SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio’s branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova and brincidofovir was licensed from Chimerix in 2019.
SymBio is a speciality pharma focused on Asia-Pacific markets and has in-licensed two orphan blood cancer products. Treakisym iv was approved for r/r low-grade NHL/MCL in 2010 and in 2016 for CLL and first-line low-grade NHL/MCL. SymBio has in-licensed liquid formulations for injection that will give Treakisym patent protection to 2031; a clinical trial is underway of the rapid-infusion liquid formulation that would reduce Treakisym infusion time from 60 minutes to 10. A Phase III trial of Treakisym in r/r diffuse large B-cell lymphoma recently reported positive results and the company has filed for a label extension. Rigosertib iv is in development for r/r HR-MDS and is in a pivotal Phase III global study in 360 patients; SymBio is enrolling patients in Japan and aims for potential filing in 2021. It intends to participate in a planned global trial of high-dose oral rigosertib in untreated HR-MDS. It in-licensed the antiviral brincidofovir from Chimerix in September 2019.
SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operational leverage.